Aeglea BioTherapeutics (NASDAQ:AGLE) Share Price Passes Below 50-Day Moving Average of $0.57
Aeglea BioTherapeutics (NASDAQ:AGLE) Share Price Passes Below 50-Day Moving Average of $0.57
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE – Get Rating)'s share price passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $0.57 and traded as low as $0.47. Aeglea BioTherapeutics shares last traded at $0.49, with a volume of 81,533 shares traded.
Aeglea 生物治療學公司（NASDAQ：AGLE-獲取評級）的股價在周四交易期間低於其 50 日移動平均線。該股票的 50 日移動平均線為 0.57 美元，交易價格低至 0.47 美元。艾格勒生物治療股票最後交易價為 0.49 美元，交易量為 81,533 股。
Wall Street Analysts Forecast Growth
華爾街分析師預測增長
A number of equities research analysts have recently issued reports on the stock. Wells Fargo & Company raised shares of Aeglea BioTherapeutics from an "equal weight" rating to an "overweight" rating and increased their price target for the stock from $1.50 to $2.00 in a report on Friday, October 28th. StockNews.com assumed coverage on shares of Aeglea BioTherapeutics in a report on Monday, January 9th. They issued a "hold" rating on the stock. Finally, Piper Sandler increased their price target on shares of Aeglea BioTherapeutics to $1.50 in a report on Tuesday, November 1st. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $1.88.
一些股票研究分析師最近發表了有關該股票的報告。富國銀行公司在 10 月 28 日（星期五）的一份報告中，將 Aeglea 生物治療藥物的股份從「同等權重」評級提高到「超重」評級，並將該股票的目標價格從 $1.50 提高到 2.00 美元。Stocknews.com 在 1 月 9 日（星期一）的一份報告中承擔了埃格勒生物治療學股份的報導。他們對股票發出了「持有」評級。最後，派珀·桑德勒在 11 月 1 日（星期二）的一份報告中，將 Aeglea 生物治療學股份的價格目標提高到 1.50 美元。三位投資分析師將該股票評級為持有評級，其中三名分析師向該公司發出買入評級。根據 MarketBeat.com 的數據，該股票的平均評級為「適度買入」，平均價格目標為 1.88 美元。
Aeglea BioTherapeutics Stock Up 2.7 %
AEGLEA 生物治療庫存上漲 2.7%
The business's 50-day simple moving average is $0.57 and its 200 day simple moving average is $0.60. The firm has a market capitalization of $30.32 million, a P/E ratio of -0.43 and a beta of 1.66.
該業務的 50 天簡單移動平均線為 0.57 美元，其 200 天的簡單移動平均線為 0.60 美元。該公司的市值為 30.32 萬美元，市盈率為 -0.43，測試版為 1.66。
Institutional Inflows and Outflows
機構流入和流出
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Two Sigma Advisers LP grew its holdings in shares of Aeglea BioTherapeutics by 76.9% in the third quarter. Two Sigma Advisers LP now owns 409,900 shares of the biotechnology company's stock worth $216,000 after purchasing an additional 178,200 shares during the last quarter. Ghost Tree Capital LLC grew its holdings in shares of Aeglea BioTherapeutics by 8.1% in the third quarter. Ghost Tree Capital LLC now owns 1,000,000 shares of the biotechnology company's stock worth $526,000 after purchasing an additional 75,000 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Aeglea BioTherapeutics by 5.6% in the second quarter. Goldman Sachs Group Inc. now owns 1,187,293 shares of the biotechnology company's stock worth $600,000 after purchasing an additional 62,504 shares during the last quarter. Nantahala Capital Management LLC grew its holdings in shares of Aeglea BioTherapeutics by 21.1% in the second quarter. Nantahala Capital Management LLC now owns 3,877,311 shares of the biotechnology company's stock worth $1,958,000 after purchasing an additional 676,718 shares during the last quarter. Finally, Bain Capital Life Sciences Investors LLC grew its holdings in shares of Aeglea BioTherapeutics by 87.8% in the second quarter. Bain Capital Life Sciences Investors LLC now owns 5,347,689 shares of the biotechnology company's stock worth $2,701,000 after purchasing an additional 2,500,000 shares during the last quarter. 78.01% of the stock is currently owned by institutional investors.
一些機構投資者和對沖基金最近買賣了該業務的股票。兩個西格瑪顧問 LP 在第三季度增長了 Aeglea 生物治療學的股份持有 76.9％。兩個西格瑪顧問 LP 現在擁有該生物技術公司的股票的 409,900 股價值 $216,000 在上一季度購買了額外的 178,200 股股票。幽靈樹資本有限責任公司在第三季度增加了 Aeglea 生物治療學股份的持有量為 8.1％。鬼樹資本有限責任公司現在擁有該生物技術公司股票的 100 萬股，價值 526,000 美元，在上一個季度購買了 75,000 股額外的 75,000 股。高盛集團在第二季度增加了其 Aeglea 生物治療藥物股份的持有量 5.6%。高盛集團在上一季度額外購買 62,504 股股票後，現在擁有該生物技術公司股票的 1,187,293 股價值 60 萬美元。楠塔哈拉資本管理有限責任公司在第二季度增長了其 Aeglea 生物治療學股份的持有量 21.1％。南大哈拉資本管理有限責任公司現在擁有該生物技術公司股票的 3,877,311 股價值 1,958,000 美元，在上個季度額外購買 676,718 股股票後。最後，貝恩資本生命科學投資者有限責任公司在 Aeglea 生物治療學的股份在第二季度增長了 87.8％。貝恩資本生命科學投資者有限責任公司現在擁有該生物技術公司股票的 5,347,689 股價值 2,701,000 美元，在上一季度購買了 2,500,000 股。78.01％ 的股票目前由機構投資者擁有。
About Aeglea BioTherapeutics
關於艾格列生物治療
(Get Rating)
(取得評分)
Aeglea Biotherapeutics, Inc is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency.
Aeglea BioTheraptics, Inc 是一家臨床階段的生物技術公司，致力於開發下一代人類酵素療法，作為罕見和其他高負擔疾病的破壞性解決方案。其產品聚乙胺精氨酸酶正處於治療精氨酶 1 缺乏症的 3 期關鍵試驗中。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on Aeglea BioTherapeutics (AGLE)
- Does Oil Services Firm NOV Have Enough Energy To Maintain Rally?
- Shopify Clears Cup-With-Handle Base: Can Momentum Continue?
- Chevron Delights Shareholders with $75 Billion in Share Buybacks
- The Future Of E-Commerce: Analysis And New Data
- Levi Strauss Is A Good Fit For Income Investors
- 獲取有關艾格勒生物療法研究報告的免費副本
- 石油服務公司 NOV 是否有足夠的能量來維持反彈？
- Shopify 清除了帶手柄的杯子底座：動力可以繼續嗎？
- 雪佛龍以 750 億美元的股份回購令股東感到滿意
- 電子商務的未來：分析與新數據
- 列維·施特勞斯是一個非常適合收入投資者
Receive News & Ratings for Aeglea BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收 Aeglea 生物治療的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Aeglea 生物治療及相關公司的最新新聞和分析師評級的簡要每日摘要。